{
  "docId": "019de070-c58c-706c-98f1-9eec26811648",
  "docSlug": "2a1e5b2d3a1cb25fe50abb3e75ae9bdf",
  "documentTitle": "Alkermes | Investor Day Presentation Deck | 144 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 132,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "thesis_headline",
  "function": "quantify_opportunity",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "Includes clinical efficacy/safety data and commercial value proposition.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-c58c-706c-98f1-9eec26811648/20",
  "deckHref": "/decks/019de070-c58c-706c-98f1-9eec26811648",
  "deckJsonHref": "/decks/019de070-c58c-706c-98f1-9eec26811648.json",
  "deckAnchorHref": "/decks/019de070-c58c-706c-98f1-9eec26811648#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.38,
        "x": 0.58,
        "y": 0.75
      },
      "kind": "list",
      "text": "Target well-defined healthcare provider call universe at launch. Implement patient access programs designed to mitigate payer restrictions early in launch.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9456ce7c-3ed1-42dc-9615-845f3b5773f1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.1,
        "x": 0.58,
        "y": 0.38
      },
      "kind": "metric",
      "text": "2.0x",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b1e6e40-dccd-454c-8bb3-010f5bea364c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.1,
        "x": 0.58,
        "y": 0.25
      },
      "kind": "metric",
      "text": "57%",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "41f14c7f-09ae-4b5b-b621-d5f0223bae41",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.06,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "Daily oral investigational antipsychotic designed to offer efficacy of olanzapine for adults with schizophrenia and adults with bipolar I disorder. Addition of samidorphan intended to mitigate olanzapine-associated weight gain. PDUFA date June 1, 2021. Anticipated launch H2 2021.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9eed6c64-41cb-452c-a3ce-8a43764b78af",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.38,
        "x": 0.58,
        "y": 0.48
      },
      "kind": "paragraph",
      "text": "ENLIGHTEN-2: Multicenter, double-blind, randomized, phase 3 study that evaluated the weight gain profile of LYBALVI (ALKS 3831) compared to olanzapine over six months in 561 patients with stable schizophrenia.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a83cff65-0fc1-4777-ad51-50f034c87985",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "*The brand name LYBALVI™ has been conditionally accepted by the FDA and will be confirmed upon approval. ** NDA resubmission under review following FDA Complete Response Letter and records requests relating to manufacturing of LYBALVI.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96bed060-7fc8-4639-9278-7cc790f13c9d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "LYBALVI™*: Potential New Revenue Driver in Oral Atypical Antipsychotic Market",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d368abd2-4941-4634-a1b8-2a7879feab24",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 10,
      "beatId": "e69bd338-b010-4d79-bb12-76f71bdac0a3",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "Slides 10-20 outline the company's value enhancement plan and strategic approach.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 23,
      "from": 15,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "016a3177-fde8-4bf5-87dc-d18694e9ff64",
      "evidence": "Slides 15-23 discuss revenue growth drivers and the importance of cost management.",
      "position": 0,
      "objective": "To highlight the cost of inaction and the benefits of Alkermes' growth strategy",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}